← Who reports today · Health Care
LH · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 5.8% y/y to $3.73B, operating margin 12.1% vs 11.2%, net income $299M (+25.6% y/y).
Net earnings attributable to Labcorp Holdings Inc.
$299M
up 25.6% y/y
Revenues
$3,731M
up 5.8% y/y
Operating income
$452M
up 14.5% y/y
Gross profit
$1,112M
up 6.3% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenues | $3,731 · +5.8% |
| Cost of revenues | $2,619 · +5.6% |
| Gross profit | $1,112 · +6.3% · 29.8% margin |
| Selling, general, and administrative expenses | $577 · −0.4% |
| Amortization of intangibles and other assets | $78.1 · +14.3% |
| Restructuring and other charges | $5.1 · +24.4% |
| Operating income | $452 · +14.5% · 12.1% margin |
| Interest expense | $61.1 · +7.0% |
| Investment income | $5.6 · +229% |
| Equity method loss, net | $6.2 · +265% |
| Other, net | $3.5 · −89.3% |
| Earnings from operations before income taxes | $386 · +26.8% |
| Provision for income taxes | $87.3 · +31.5% · 22.6% effective rate |
| Less: Net earnings attributable to the noncontrolling interest | $0.4 · +0.0% |
| Net earnings attributable to Labcorp Holdings Inc. | $299 · +25.6% · $3.64/sh · 8.0% margin |
Verdict: revenue grew 5.8% y/y to $3.73B, operating margin 12.1% vs 11.2%, net income $299M (+25.6% y/y).
Share repurchase authorization was increased by $1.0 billion.
Source and notation
Source: Labcorp press release, 8-K EX-99.1 of 07/30/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: LH, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “LH Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/lh/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/lh/q2-2026"><img src="https://whoreportstoday.com/t/lh/q2-2026/sankey.png" alt="LH Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/lh/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/lh/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/lh/q2-2026">LH Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Labcorp raised full-year revenue growth guidance to 5.4% to 6.3%.
- Gross margin was 29.8% vs 29.7% a year earlier.
- Operating income was $452M, a 12.1% margin vs 11.2% a year earlier.
- The effective tax rate was 22.6% vs 21.8% a year earlier.
- Diluted EPS was $3.64 vs $2.84 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
LH — a laboratory services company that runs medical tests for doctors, hospitals and patients and provides laboratory and research services that help pharmaceutical, biotech and medical device companies develop and register products.
It reports two segments: Diagnostics Laboratories and Biopharma Laboratory Services; diagnostics accounted for about 78% of 2025 revenue. · Source: annual report (Form 10-K, SEC)
More reports: LLY · Q2 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q2 2026 · MRNA · Q2 2026 · MTD · Q2 2026 · PFE · Q2 2026 · PODD · Q2 2026 · REGN · Q2 2026 · RMD · Q4 FY2026 · all reports